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The differential diagnosis for children with
diabetes includes a group of monogenic diabetic
disorders known as maturity-onset diabetes of the
young (MODY). So far, six underlying gene de-
fects have been identified. The most common sub-
types are caused by mutations in the genes encod-
ing the transcription factor HNF-1a (MODY 3)
and the glycolytic enzyme glucokinase (GCK)
(MODY 2). MODY 2 is the most benign form of
diabetes as the threshold for glucose sensing is el-
evated resulting in mild, regulated hyperglycemia.
MODY 2 may usually be treated with diet alone
without risk of microvascular complications. Pa-
tients with MODY usually present as children or
young adults. Genetic testing for MODY in dia-
betic subjects is often not performed because of 
the costs and its unavailability in Switzerland. We
describe the impact of the genetic analysis for
MODY 2 on diabetes management and treatment
costs in a five-year-old girl. The patient and her
diabetic mother were both found to have a het-
erozygous missense mutation (V203A) in the glu-
cokinase gene. The five-year-old girl was started
on insulin therapy for her diabetes but because her
HbA1c remained between 5.8–6.4% (reference
4.1–5.7%) and her clinical presentation suggested
MODY insulin was discontinued. She is now well
controlled on a carbohydrate controlled diet regi-
men only. Omission of insulin treatment made
regular blood glucose monitoring unnecessary and
removed her risk of hypoglycemia. Costs for the
genetic analysis were 500 Euro. At our centre costs
for diabetes care of a patient with type 1 diabetes
are approximately 2050 Euro/year compared to
410 Euro/year for the care of a patient with
MODY 2. In addition, a diagnosis of MODY 2
may reassure patients and their families, as mi-
crovascular complications are uncommon. Thus
there are both health and financial benefits in di-
agnosing MODY 2. We recommend genetic test-
ing for MODY 2 in clinically selected patients even
though this analysis is currently not available in
Switzerland and costs are not necessarily covered
by the health insurances.
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Not all children with diabetes have type 1 di-
abetes. One differential diagnosis is maturity-
onset diabetes of the young (MODY) which
accounts for approximatively 1–2% of diabetes in
Europe [1]. MODY is a group of monogenetic
forms of diabetes which are characterized by a 
b-cell dysfunction with an autosomal dominant 
inheritance and an early onset (<25 y) of diabetes
mellitus that is not insulin dependent [2]. To date,
six subtypes of MODY have been genetically 
characterized [3]. Mutations in pancreatic β-cell
transcription factor genes cause MODY 1 (hepa-
tocyte nuclear factor (HNF)-4a, OMIM 125850),
MODY 3 (HNF-1a, OMIM 600496), MODY 4
(insulin promoter factor-1, OMIM 606392),
MODY 5 (HNF-1β, OMIM 604284) and MODY
6 (Neuro-D1, OMIM 606394) and mutations in
the gene encoding the glycolytic enzyme glucoki-
nase (GCK) cause MODY 2 (OMIM 125851). 
Studies from the UK, France and Italy have
shown that MODY 2 and MODY 3 are the most
common forms of MODY in children in Europe
[1, 4]. MODY 2 and MODY 3 differ fundamen-
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tally in their underlying defect and in their clinical
impact, thus necessitating different therapeutic ap-
proaches [5–8]. Patients with MODY 2 merely
have a higher threshold for insulin secretion from
the glucose-sensing b-cell of the pancreas result-
ing in life long mild regulated hyperglycemia that
deteriorates little with age. Thus, patients with
MODY 2 rarely suffer from diabetic complications
and may be managed by a healthy lifestyle alone as
long as they do not develop type 2 diabetes as well
[1]. In contrast, patients with MODY 3 have a pro-
gressive defect in insulin secretion frequently re-
sulting in severe and progressive hyperglycemia in
adult life. Therefore patients with MODY 3 need
intensive glycemia treatment, usually with sulpho-
nylureas, to prevent significant long term mi-
crovascular complications [1].
Clinical features can help determine which di-
abetic children have MODY and the likely clinical
subtype. MODY patients, in contrast to type 1 do
not become severely insulin deficient within 2
years of diagnosis. A detailed family history (in-
cluding testing of parents) is likely to show auto-
somal dominant inheritance of diabetes in MODY
but this is uncommon in type 1 diabetes. In con-
trast to type 2 diabetes in children MODY patients
are typically lean. Clinical characteristics also help
to distinguish between MODY 2 and MODY3. A
patient with MODY 2 presents with a fasting blood
sugar which is higher than 5.5 mmol/l even at a
very young age, but the blood sugar will only in-
crease slightly (typically <3.0 mmol/l) during an
oral glucose tolerance test (OGTT) [9]. In con-
trast, a patient with MODY 3 may have fasting
blood glucose values lower than 5.5 mmol/l in
early childhood, but these values will increase with
age, and at any age blood sugar usually increases
by more than 3.0 mmol/l at 2 hours during an
OGTT [9]. The differences in OGTT cannot be
used for diagnosis as they are not sufficiently sen-
sitive or specific especially below the age of 10
years [9]. To make a diagnosis of the specific type
of MODY genetic testing is required. However ge-
netic testing for monogenetic forms of diabetes has
been considered controversial because of its high
costs. Routine genetic testing for MODY 2 is cur-
rently not available in Switzerland and costs for ge-
netic testing are not routinely covered by health
care providers.
Here we present a five-year-old girl and her
family in whom genetic testing revealed a glucok-
inase mutation confirming MODY 2. Costs of ge-
netic testing are weighed against intensive diabetes
control management, which is necessary for all
forms of diabetes apart from MODY 2. 
Case presentation
A 5-year-old Italian girl was noted to be more tired,
lethargic, and pale. As her diabetic mother suffered from
similar symptoms when her diabetes was first diagnosed at
age 25, she measured several random blood glucose levels
on her daughter which were between 6.9 and 8.2 mmol/l.
At her Primary Care Physician’s office, the girl’s HbA1c
was 7% but spot urine analysis revealed neither glucose
nor ketones. The girl was referred to our centre for fur-
ther evaluation and treatment.
At her first visit we found a healthy, 4 3/12 year old
girl. Her weight was 18.8 kg (P90), height was 107 cm
(P75-90), and her complete physical exam was normal.
Her random blood glucose was 8.9 mmol/l, HbA1c was
6.8% (reference 4.1–5.7%). Past medical history revealed
a normal pregnancy except for slightly elevated maternal
blood glucose levels, which were controlled by diet alone;
her birth weight at term was 2900 g (P10). Postnatal
growth and development were normal. The patient’s
family history revealed at least five family members over
three generations who were diagnosed with mild diabetes
(figure 1). The available clinical data of these affected fam-
ily members are summarized in table 1.
For further evaluation an oral glucose tolerance test
(OGTT) was performed [10]. During the OGTT her
blood glucose increased from 6.8 mmol/l to 11.8 mmol/l
at 30 min but declined to 8.1 mmol/l at 120 min consis-
tent with the diagnosis of impaired glucose tolerance.
However, repeated fasting and random glucose levels on
occasions exceeded 7.0 mmol/l and 11.2 mmol/l respec-
tively, consistent with the diagnosis of diabetes mellitus
according to the WHO criteria. Serum C- peptide and
insulin levels were normal. Repeat HbA1c was 6.6% (ref-
erence 4.1–5.7%), fructosamine was 265 mmol/l (reference
205–285 mmol/l), and antibodies (anti-GAD, -IA2, -in-
sulin and -b-cell) were all negative. 
The initial differential diagnosis was the early presen-
tation of type 1 diabetes [11] or MODY. Therefore, the
patient was hospitalised for one week, started on a quali-
tative and quantitative diet, and a trial of daily subcuta-
neous insulin injections (4 units glargine, Lantus®, Aven-
tis Pharma; (0.2 U/kg/d)) controlled by blood glucose
monitoring (4–5 times per day). However, follow-up vis-
its in our outpatient clinic three and six months later
revealed an unchanged HbA1c under this treatment. Also,
insulin treatment and the fixed diet regimen made the daily
life of the patient and her family very stressful as the five-
year-old protested vigorously against the subcutaneous in-
sulin injections and often refused to eat the planned meals,
which put her at risk for hypoglycemia on insulin treat-
ment. Thus insulin treatment was discontinued. 
Figure 1
Family tree with
unaffected subjects
shown in white, clini-
cally affected sub-
jects shown in grey,
and subjects geneti-
cally diagnosed with
MODY 2 shown in
black. The arrow
points to the index
patient.
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Based on the clinical presentation with elevated fast-
ing glucose values, mild increase of blood sugars during
OGTT, mildly elevated HbA1c, as well as the lack of re-
sponse to insulin treatment and the typical family history
of long standing diabetes without complications in several
family members, we recommended genetic testing for
MODY 2. 
Pt Patient Age at dx Symptoms Treatment A1c BMI (kg/m2) Complications Other data
(age in years) at diagnosis (dx)
1 Index pt (5) 5 years tiredness Diet, insulin (glargine) 6.1% 16.6 None 2900 g at birth
and repaglinide
2 Brother (4) 4 years none Diet 6.4% None 4800 g at birth
3 Mother (35) 25 years tiredness Diet, glibornurid 6.0% 30 None 2 normal 
and metformin pregnancies
4 Maternal 40ies thirst, tiredness Diet, metformin and 6.5–7% 31 None 2 normal 
Grandmother (61) insulin pregancies
5 Maternal 50ies none Diet and oral drugs ? obese None
Great-Uncle (65)
6 Great-Grandmother (?) 60ies ? Diet and oral drugs ? ? Unknown Died of pneumonia
(was on insulin for 1 year)
Table 1
Clinical characteristics of the patients.
Methods 
Blood was obtained from the patient and her diabetic
mother and genomic DNA was extracted from peripheral
leukocytes (QIAamp®, Qiagen). Exons 1–10 of the gluco-
kinase gene on chromosome 7p15-p13 were PCR-ampli-
fied and purified as previously described [12]. PCR prod-
ucts were sequenced in both directions using the BigDye
Terminator Cycle sequencing chemistry (Applied Biosys-
tems) according to the manufacturer’s instructions. Reac-
tions were then run on an ABI Prism 3100 DNA Se-
quencer (Applied Biosystems) and analysed using Se-
quence Analysis (Applied Biosystems) and Staden Muta-
tion Analysis software.
Results and follow-up
Genetic analysis revealed that our patient 
was heterozygous for the missense mutation
GTG>GCG in exon 6 of the glucokinase gene 
resulting in the substitution of alanine for valine 
at codon 203 (V203A) (figure 2). The patient’s
mother was heterozygous for the same mutation
confirming the autosomal dominant trait. This
mutation has been previously described [5, 13].
Recently reported functional studies of the mutant
V203A GCK protein have confirmed that this is
an aetiological mutation as it markedly alters both
the IC50 and Vmax of the enzyme [14–16].
The diagnosis of MODY 2 in our patient con-
firmed our clinical decision that this diabetic child
may be managed by diet alone. Follow-up studies
of MODY 2 patients have shown no or little com-
plications [1]. Thus insulin treatment was stopped.
Three months after discontinuing insulin our
patient presented healthy, her fasting glucose was
7.1 mmol/l and her HbA1c was 6.3%. At this time
we also drew fasting glucose and HbA1c on her
four-year-old brother (5.7 mmol/l and 6.4%) and
on her father (4.4 mmol/l and 5.2%). While glu-
cose and HbA1c were normal in the father, the
presence of a fasting glucose >5.5 mmol/l in the
patient’s brother is consistent with the diagnosis of
MODY 2. Thus we recommended including the
younger brother in the healthy eating diet regimen
at home. Overall the family was very happy about
the changes in the daily management of the dia-
betes, not having to give their child daily insulin
injections any longer and measuring glucose only
once a week and during illnesses. Furthermore, it
was also an enormous psychological relief to the
parents that after discontinuation of the insulin
treatment they did not have to worry about hypo-
glycemia any longer. In addition, with respect to
the future of their child diagnosis of MODY 2 was
a big relief as it is rarely associated with complica-
tions. 
As the costs for genetic analysis for MODY 2
are currently not routinely covered by the health
insurances in Switzerland, we evaluated the cost ef-
fectiveness of the genetic testing in our patient. We
calculated the costs for testing and the costs for
intensive diabetes control and treatment manage-
ment as recommended for type 1 diabetes. The
genetic analysis for MODY 2 (and MODY 3) is
currently offered for 500 Euro for the index pa-
tient and for 120 Euro for relatives at the Molec-
ular Genetics Department of the Royal Devon &
Exeter NHS Foundation Trust (Exeter, UK)
(http://www.diabetesgenes.org). Initially, routine
diabetes control in our patient – as recommended
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for type 1 diabetic children-included daily blood
glucose monitoring (1150 Euro/year), insulin in-
jections (300 Euro/year), and follow-up visits at
our diabetes clinic four times per year (600 Euro/
year). Because diabetic children under insulin
treatment have a high risk for hypoglycemia, emer-
gency treatment for hypoglycemia may even cause
additional costs. Not knowing the underlying de-
fect of MODY diabetes in our patient, 
we would have recommended follow up visits 2 to
4 times per year for 300–600 Euro/year whereas
after genetic diagnosis of MODY 2 we feel safe see-
ing her once per year. In summary, management
changes after genetic testing for MODY 2 in our
patient outweigh the costs for the genetic analysis
in less than 2 years.
Figure 2
Sequence analysis
showing the het-
erozygous GTG>GCG
mutation in the pa-
tient but not the con-
trol. This mutation
causes the V203A
mutation in the
glucokinase. 
PATIENT
CONTROL
Discussion
MODY is a rare cause of diabetes mellitus in
the general population. However, in a lean, young
child of Caucasian ancestry presenting with mild
or moderate hyperglycemia and variably reduced
insulin secretion, it might be the most likely diag-
nosis after excluding latent type 1 diabetes melli-
tus [2, 17]. Although it is still expensive and thus
controversial to diagnose MODY 2 by diagnostic
genetic analysis routinely, we show here that ge-
netic testing in clinically selected patients is in fact
cost effective as well as having major clinical ben-
efit. 
MODY 2 is considered benign when compar-
ing the risk for possible long term complications
with all other forms of diabetes which means that
pharmacological treatment is rarely needed in
contrast to all other forms of diabetes. For MODY
2 follow-up visits may be recommended yearly, and
patients are typically well controlled by diet alone.
In contrast, patients with MODY 3 should be
monitored more often as their glucose homeo-
stasis worsens over time requiring treatment with
sulfonylurea at some point [1, 7, 8]. Thus, clinical
diagnosis of MODY without knowing the under-
lying defect specifically will not provide enough in-
formation to avoid under-treating or over-treating
patients with MODY 3 or MODY 2 respectively. 
Moreover, for female patients with MODY 2,
it may be critical to know the exact diagnosis dur-
ing pregnancy. Hattersley et al. [18] have shown
that children with mutations in the GCK gene
were born with low birth weights when the mother
was unaffected. In contrast, affected, untreated
mothers had affected off springs of normal birth
weight, and finally affected mothers carrying un-
affected fetus gave birth to overweight babies.
Thus, insulin secretion from the pancreatic b-cell
in the fetus is regulated by the maternal blood glu-
cose levels and the fetal mutation status [18].
Therefore, if a pregnant woman with mild gesta-
tional diabetes due to MODY 2 is treated with in-
sulin to achieve euglycemia, and the fetus carries
the GCK mutation (a 50% chance due to the au-
tosomal dominant inheritance), the fetus might
suffer from intrauterine growth retardation
(IUGR) [19]. Insulin-dependent fetal growth
might be impaired under euglycemic conditions
because the fetus carrying a GCK mutation needs
higher maternal blood glucose concentrations for
stimulating insulin secretion from his b-cell. 
In conclusion, we are convinced that in care-
fully selected diabetic patients – such as young chil-
dren presenting with fasting hyperglycemia, but
only moderate increase of blood sugar during
OGTT, and a positive family history – genetic test-
ing for MODY 2 is a vital clinical tool as well as
being financially beneficial. We hope that routine
testing for those selected patients will become
available in Switzerland in the near future. Mean-
while this report may also help to convince Swiss
health insurance companies that covering the costs
for the molecular analysis for patients with a clin-
ical picture that is highly suggestive for MODY 2
is a worthwhile investment. 
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